CTLA4 and melanoma: A large fraction of patients with cancer, including melanoma, do not experience tumor regression after single-checkpoint or dual-checkpoint blockade with anti-PD-1 and anti-CTLA-4 mAbs, likely due in part to insufficient spontaneous antitumor T cell immunity.